Market Movers

CVS Health Corporation’s Stock Price Soars to $45.28, Marking a Robust 2.82% Increase

By December 19, 2024 No Comments

CVS Health Corporation (CVS)

45.28 USD +1.24 (+2.82%) Volume: 23.76M

CVS Health Corporation’s stock price sees a promising rise of +2.82% this trading session, reaching $45.28 with a robust trading volume of 23.76M, despite a challenging year-to-date percentage change of -42.65%.


Latest developments on CVS Health Corporation

CVS Health Corporation has been facing a tumultuous time in the stock market recently, with shares falling a further 17% in the past week alone. The healthcare giant has been hit from all sides, with challenges in its insurance business persisting and accusations of filling illegal opioid prescriptions. President Trump’s comments about ‘knocking out’ drug industry middlemen have also had a negative impact on CVS, UnitedHealth, and Cigna stock prices. The company’s stock is currently at its worst month in decades, with the Justice Department even suing CVS for alleged violations. Despite these challenges, CVS Health remains resilient, announcing pricing of maximum tender offers and debt tender offers amidst the stock price turmoil.


CVS Health Corporation on Smartkarma

Analysts at Baptista Research on Smartkarma have provided insightful coverage of Cvs Health Corp, highlighting key drivers of growth and strategic initiatives. In their report titled “CVS Health Corporation: Expansion & Optimization of Health Services As A Critical Factor Driving Growth! – Major Drivers,” they discuss the company’s third-quarter 2024 earnings report, noting a 6% increase in revenue to approximately $95.4 billion. However, challenges in the Health Care Benefits segment were indicated by the adjusted earnings per share of $1.09. The analysts’ bullish sentiment suggests optimism for CVS Health’s future prospects.

Furthermore, Baptista Research‘s analysis in the report “CVS Health Corporation: Strategic Leverage in Pharmacy Benefit Management (PBM) and Insurance Operations! – Major Drivers” delves into the company’s performance in the second quarter of 2024. They highlight mixed financial results, with adjusted earnings per share of $1.83 and revenues exceeding $91 billion. Operating cash flow of $8 billion for the first half of the year was supported by strong performances in the Health Services and Pharmacy & Consumer Wellness segments. This positive assessment underscores the potential strategic leverage CVS Health holds in its key operations.


A look at CVS Health Corporation Smart Scores

FactorScoreMagnitude
Value5
Dividend5
Growth3
Resilience3
Momentum3
OVERALL SMART SCORE3.8

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Based on the Smartkarma Smart Scores, CVS Health Corp seems to have a positive long-term outlook. With high scores in both the value and dividend categories, the company appears to be a strong investment option for those looking for stability and potential returns. While the growth, resilience, and momentum scores are not as high, the overall outlook for CVS Health Corp remains promising.

As an integrated pharmacy health care provider, CVS Health Corporation offers a wide range of services including pharmacy benefit management, mail order, retail and specialty pharmacy, disease management programs, and retail clinics. With a strong presence in the U.S., the District of Columbia, and Puerto Rico, CVS Health Corp is well-positioned to continue providing essential healthcare services to communities across the country.


Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.


 

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Analytics and News
  • ✓ Events & Webinars